156-Engineering Myeloid Cells for Cancer Immunotherapy
This paper discusses the emerging field of engineering myeloid cells, specifically macrophages, for cancer immunotherapy. It begins by contrasting the promising but challenging Chimeric Antigen Receptor T-cell (CAR-T) therapies, which face issues like toxicity and limited efficacy against solid tumors, with alternative approaches like CAR-Natural Killer (CAR-NK) cells and CAR-macrophages (CAR-Ms). The commentary primarily explores the potential of CAR-Ms to overcome the limitations of CAR-T cells, noting their improved safety profile-exhibiting only low-grade cytokine release syndrome (CRS)…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.